Rush University Medical Center
Chicago, Illinois, 60612, United States
NCT Number: NCT06691256
Globally, >47M individuals live with dementia, with new incidence of 7.7M annually. Medication mismanagement is one of the most common and concerning risk factors in people with dementia (PwD), as it leads to undertreatment, emergency room visits, hospital admissions/readmissions, and serious adverse events. 3M older U.S. adults are admitted to nursing homes due to drug-related adherence problems with costs >$14B/year. Furthermore, 30% of hospital admissions of older adults are drug related with 11% attributed to medication non-adherence and 17% to adverse drug reactions. While Alzheimer's disease (AD) & type 2 diabetes mellitus (DM) individually have considerable morbidity & mortality, they often occur together, worsening adverse outcomes, quality of life, & care costs. This is especially true as the AD/DM combination creates a complex balancing act of med management & symptom monitoring in older populations. While the goal is to keep older adults with dementia at home as long as possible, these challenges lead to untold personal & family suffering, as well as billions in potentially avoidable healthcare costs annually. The HiDO-ALZ platform will solve these challenges by automating medication administration for PwD to eliminate mismanagement, decrease caregiver burden, reduce healthcare utilization, and facilitate PwD to age in place. HiDO is being developed as an automated, AI driven medication dispensing and direct observation platform to optimize adherence. The device integrates medication dispensing, dose administration time, medication synchronization, & pair of front-facing cameras to validate the right meds, right route, right time, right dosage to the right patient (5R's). Cameras record every dose using facial recognition & provide real -time medication consumption recordings. Through cloud connectivity, providers & caregivers have access to video observation logs, dose administration time, adherence trends, & longitudinal adherence via web dashboard. Patients & caregivers can easily setup complex medication protocols in minutes using a smartphone app. The device then alerts patients and dispenses up to 7 different types of meds simultaneously, with up to 90 days of medication. Connected data sources including remote blood pressure and weight measurements, as well as electronic health record lab results and videoconferencing integrate in a single dashboard. The project will build on successful Phase I, in which the medication dispensing unit was updated with modifications for dementia, passed all bench testing, and was successfully validated in pilot usability with dementia subjects. Phase II will expand the foundation with four Aims: 1) Enhance device with remote sensors for diabetes management, expanded data integration, and video conferencing, 2) Test enhanced platform for usability in dementia subjects, 3) Transition the design to formal manufacturing process to ensure system meets performance standards and regulatory requirements & produce pre-production devices for testing, & 4) Conduct in-home clinical trial to demonstrate adherence and efficacy.
This study is active but is not currently recruiting participants.
65 year and older
All sexes
Interventional
Phase 2
Chicago, Illinois, 60612, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HiDO-ALZ platform, an AI-driven medication dispensing and observation system designed to improve adherence in individuals with dementia and diabetes.
Time frame: Measurements are collected daily and weekly over 12 months.
The primary outcome focuses on improving medication adherence among participants using the HiDO-ALZ system, as compared to standard care. Medication adherence is measured through the system's automated monitoring, which utilizes facial recognition to verify identity and track each dose administered. The HiDO-ALZ platform records the timing and accuracy of each dose taken, providing a comprehensive adherence rate over the study period. This adherence data will be evaluated against adherence rates in the standard care group, aiming to demonstrate the system's effectiveness in reducing missed doses and optimizing medication management for individuals with dementia.
Time frame: Measurements are collected at baseline, 6 months, and 12 months for both adherence and biomarker levels.
This outcome measures the average change in blood glucose levels for participants in the experimental group using the HiDO-ALZ system compared to the control group receiving standard care. Blood glucose levels will be measured at baseline, 6 months, and 12 months, with the change calculated as the difference from baseline to each subsequent time point.
Unit of Measure: Milligrams per Deciliter (mg/dL)
Time frame: Measurements are collected at baseline, 6 months, and 12 months for both adherence and biomarker levels.
This outcome measures the average change in HbA1c levels for participants in the experimental group compared to the control group. HbA1c levels will be monitored at baseline, 6 months, and 12 months, with changes calculated as the difference from baseline.
Unit of Measure: Percentage (%)
Time frame: Measurements are collected at baseline, 6 months, and 12 months for both adherence and biomarker levels.
This outcome measures the average change in serum creatinine levels for participants in the experimental group compared to the control group. Measurements will be taken at baseline, 6 months, and 12 months, with changes calculated from baseline values.
Unit of Measure: Milligrams per Deciliter (mg/dL)
Time frame: Measurements are collected at baseline, 6 months, and 12 months for both adherence and biomarker levels.
This outcome measures the average change in GFR, an indicator of kidney function, for participants in the experimental group compared to the control group. Measurements will be taken at baseline, 6 months, and 12 months, with changes calculated from baseline values.
Unit of Measure: Milliliters per Minute per 1.73 m² (mL/min/1.73 m²)
Time frame: Measurements are taken monthly over the 12-month study duration.
Weight will be tracked monthly for participants in the experimental group using Bluetooth-enabled devices integrated with the HiDO-ALZ platform. The weight data, recorded in kilograms, will provide insights into any weight changes over the 12-month study period, aiding in the assessment of overall health status.
Time frame: Measurements are taken monthly over the 12-month study duration.
Blood pressure will be measured monthly for each participant using Bluetooth-enabled devices connected to the HiDO-ALZ system. Data, recorded in mmHg, will include both systolic and diastolic values to monitor blood pressure trends and assess the intervention's impact on cardiovascular health over time.
Time frame: Measurements are taken monthly over the 12-month study duration.
Heart rate will be recorded monthly in beats per minute (bpm) for participants in the experimental group through Bluetooth-enabled devices connected to the HiDO-ALZ platform. Monthly tracking will allow for the evaluation of heart rate stability and potential changes associated with the intervention.
HiDO Technologies
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06203106
ALS, Adnexal Diseases
New York, United States
View Trial DetailsNCT05508789
Alzheimer Disease, Brain Diseases
ABB, Argentina
View Trial DetailsNCT04692441
Alzheimer Disease, Brain Diseases
Seattle, Washington, United States
View Trial DetailsNCT05607732
Alzheimer Disease, Brain Diseases
Chicago, Illinois, United States
View Trial Details